Sobi acquires emapalumab and related assets
Swedish Orphan Biovitrum AB (publ)?(Sobi?) (STO:SOBI)?has signed an agreement to acquire, from Novimmune?s shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded.
Through the acquisition of emapalumab, Sobi gains access to:
This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Linda Holmstr?m, Corporate Communications and Investor relations at 13:00 CEST on 12 June 2019.
- All assets relating to emapalumab including intellectual property, patent rights, data and know-how
- All relevant and highly experienced employees involved in the clinical and biopharmaceutical development of emapalumab
- Options for the shared financial rights to NI-1701 and NI-1801, two product candidates in the field of immuno-oncology
- A priority review voucher within the US Food & Drug Administration?s priority review programme, which offers companies investing in orphan drugs a cost reduction for the application fee for future products and shortens the review period. The voucher can be used or sold by Sobi.
Paula Treutiger, Head of Communication & Investor Relations |
0733?666 599 |
paula.treutiger@sobi.com |
Linda Holmstr?m, Corporate Communication & Investor Relations |
0708?734 095 |
linda.holmstrom@sobi.com |